Welcome to our dedicated page for Iperionx SEC filings (Ticker: IPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IperionX Limited (IPX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. IperionX files annual reports on Form 20-F and furnishes current information on Form 6-K, including quarterly reports, sustainability reports, notices of annual general meeting, trading halt requests and press releases related to its titanium and critical minerals operations.
Through these filings, investors can review how IperionX describes its business as an American titanium metal and critical materials company that uses patented technologies to produce high performance titanium alloys from titanium minerals or scrap titanium. Annual and quarterly reports furnished as exhibits to Form 6-K outline the status of the Titanium Manufacturing Campus in Virginia, the Titan Critical Minerals Project in Tennessee, government funding arrangements, customer programs and risk factors associated with scaling titanium production and commercialization.
Filings also document U.S. Government support, including Defense Production Act Title III investments, Industrial Base Analysis and Sustainment awards, and the Small Business Innovation Research (SBIR) Phase III Indefinite Delivery, Indefinite Quantity contract that enables task orders for titanium components. These documents provide detail on how such programs are structured and how they relate to IperionX’s plans to expand titanium capacity and develop a mineral-to-metal supply chain.
On Stock Titan, users can view these SEC submissions as they are furnished to EDGAR and use AI-powered summaries to interpret complex sections. The platform highlights key elements of IperionX’s 20-F and 6-K exhibits, helping readers quickly understand disclosures about production capacity, government contracts, critical minerals resources, financial reporting practices and other material information contained in the company’s official filings.
IPERIONX Ltd director reports initial holdings in a Form 3 filing. Director R Tony Tripeny discloses beneficial ownership of 38,777 Ordinary Shares and 51,010 Restricted Stock Units. The Ordinary Shares trade on the Australian Stock Exchange. Of the RSUs, 36,848 vest in December 2026 and 14,162 vest in December 2027.
IPERIONX Ltd director Melissa Gowdy Waller filed an initial ownership report showing she holds 486,318 Ordinary Shares and 84,771 Restricted Stock Units of the company. According to the filing, 70,609 of these RSUs vest in December 2026 and 14,162 vest in December 2027.
IPERIONX Ltd Chief Financial Officer Marcela Rocha Castro filed an initial statement of beneficial ownership. She directly holds 380,841 IPX ordinary shares and 162,001 restricted stock units, with 79,666 scheduled to vest in December 2026 and 82,335 in December 2028. She also holds options over 216,672 IPX ordinary shares at a conversion price of A$5.00 per share, expiring in April 2029. IPX ordinary shares trade on the Australian Stock Exchange.
IPERIONX Ltd director Martin Lorraine M filed an initial ownership report showing a substantial stake in the company. The filing lists direct beneficial ownership of 1,177,138 Ordinary Shares and 90,216 Restricted Stock Units.
Of the RSUs, 76,054 are scheduled to vest in December 2026 and 14,162 in December 2027. IPX Ordinary Shares trade on the Australian Stock Exchange.
IPERIONX Ltd director Beverly Wyse has reported her initial ownership in the company. She holds 639,775 IPX Ordinary Shares directly, plus options over 106,093 IPX Ordinary Shares with an exercise price of 0.87 Australian Dollars per share that expire on May 12, 2026. She also holds 84,771 Restricted Stock Units, of which 70,609 vest in December 2026 and 14,162 vest in December 2027. IPX Ordinary Shares trade on the Australian Stock Exchange (ASX).
IperionX Limited filed a Form 6-K mainly to publish correspondence with the Australian Securities Exchange after a sharp share price move. ASX queried a change in IPX’s price from a high of $6.93 on 12 March 2026 to an intraday low of $4.58 on 16 March 2026. IperionX stated it is not aware of any information or reason that would explain the trading pattern, other than previously released disclosures. The company highlighted that its half year report was released last week and noted stakeholder questions about the funding mechanics of its U.S. Department of War grants. IperionX also confirmed it remains in compliance with ASX Listing Rules, including continuous disclosure obligations.
IperionX Limited reported a larger net loss of US$34.8 million for the six months ended December 31, 2025, compared with US$16.2 million a year earlier, as it ramped research, exploration and corporate spending to build its U.S. titanium platform. Cash and cash equivalents rose to US$65.8 million, supported by an October equity placement raising about US$46 million, lifting net assets to US$108.2 million. The company continued heavy investment in property, plant, equipment and intellectual property to scale titanium production in Virginia and advance the Titan critical minerals project in Tennessee. U.S. government support remains substantial, with US$59.8 million in DPA and IBAS awards by December 31, 2025 and a separate SBIR Phase III contract mechanism of up to US$99 million in potential task orders. After period end, the DoW obligated the final US$4.6 million under the IBAS award, transferred about 290 metric tons of titanium scrap at no cost, and IperionX received a US$0.3 million prototype order from American Rheinmetall, underscoring momentum toward commercialization.
IperionX Limited is offering 1,273,179 ordinary shares pursuant to a prospectus supplement dated February 23, 2026, with an offering price of $4.11 per share under a settlement agreement. The company will receive no proceeds from this issuance.
The shares are being sold directly by the company without underwriters and are expected to settle on or prior to February 24, 2026. Ordinary shares to be outstanding immediately after this offering are stated as 339,384,070 ordinary shares.
IperionX Limited reported leadership and administrative changes. The company appointed Louisa Martino as Company Secretary, effective February 16, 2026. She brings over 15 years of experience in company secretarial and corporate advisory roles, including work on corporate compliance, capital raisings and due diligence.
On the same date, Gregory Swan will step down as Company Secretary, with the Board expressing appreciation for his contributions. IperionX also announced that its registered office and principal place of business will move to Level 5, 56 Pitt Street, Sydney NSW 2000, reflecting an updated corporate address and primary contact location.
IperionX Limited uses this shareholder letter to outline its 2026 strategy to build a fully integrated, American titanium supply chain. The company highlights commercial-scale operations in Virginia that use its patented HAMR™ and HSPT™ technologies to produce high-performance titanium from domestic scrap and minerals at substantially lower costs.
IperionX emphasizes national security and industrial goals, aiming to reshore titanium for aerospace, defense, shipbuilding, and advanced industries. Its 100% owned Titan Critical Minerals Project in Tennessee is fully permitted and moving toward a Definitive Feasibility Study in Q2 2026, targeting low-cost feedstock and potential production of heavy rare earths Dysprosium and Terbium.
The company also introduces GenX™, a next-generation continuous HAMR™ platform being advanced in Virginia. It expects key commercial-scale validation milestones in 2026 to underpin capital-efficient scaling of low-cost, American-made titanium through 2030 and beyond.